Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525 08/10/2020 Medications NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE) October 07, 2020 — Read more